A mouse model for the carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4506-4514

  Kirschner, Lawrence S ^a,b,c   Kusewitt, Donna F ^c   Matyakhina, Ludmila ^d   Towns II, William H ^b   Carney, J Aidan ^f   Westphal, Heiner ^e   Stratakis, Constantine A ^d  

^a Human Cancer Genetics Program   (United States)

^b Division of Endocrinology   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Section on Genetics and Endocrinology   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP;

ADRENAL DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LESION; CARCINOGENESIS; CARNEY COMPLEX; CELL DIFFERENTIATION; CONTROLLED STUDY; GENETIC ANALYSIS; GENOTYPE; HEART INJURY; MOUSE; NEOPLASM; NEURAL CREST CELL; NEURILEMOMA; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN DEPLETION; THYROID TUMOR; TISSUE REACTION; TISSUE SPECIFICITY; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; BONE NEOPLASMS; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; MULTIPLE ENDOCRINE NEOPLASIA; NEURILEMMOMA; OSTEOBLASTS; PROTEINS; SCHWANN CELLS; SYNDROME; THYMUS GLAND; THYROID NEOPLASMS;

EID: 19644364776     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0580     Document Type: Article

References (46)

1. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041-6.
2. Carney JA, Hruska LS, Beauchamp GD, Gordon H. Dominant Inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 1986;61:165-72.
3. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037-46.
4. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
5. Casey M, Vaughan CJ, He J, et al. Mutations In the protein kinase A Riot regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 2000;106:R31-8.
6. Cho YJ, Kim JY, Jeong SW, Lee SB, Kim ON. Cyclic AMP induces activation of extracellular signal-regulated kinases in HL-60 cells: role in cAMP-lnduced differentiation. Leuk Res 2003;27:51-6.
7. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21:8471-82.
8. Han SY, Park DY, Lee GH, Park SD, Hong SH. Involvement of type I protein kinase A in the differentiation of L6 myoblast in conjunction with phosphatidylinositol 3-kinase. Mol Cells 2002;14:68-74.
9. Kim G, Choe Y, Park J, Cho S, Kim K. Activation of protein kinase A induces neuronal differentiation of HiB5 hippocampal progenitor cells. Brain Res Mol Brain Res 2002;109:134-45.
10. Weissinger EM, Oettrich K, Evans C, et al. Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. Br J Cancer 2004; 91:186-92.
11. Tsilou ET, Chan CC, Sandrini F, et al. Eyelid myxoma in Carney complex without PRKAR1A allelic loss. Am J Med Genet 2004;130A:395-7.
12. Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003;63:5308-19.
13. Sandrini F, Matyakhina L, Sarlis NJ, et al. Regulatory subunit type I-α of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer 2002;35:182-92.
14. Barradeau S, Imalzumi-Scherrer T, Weiss MC, Faust DM. Alternative 5′-exons of the mouse cAMP-dependent protein kinase subunit RIα gene are conserved and expressed in both a ubiquitous and tissue-restricted fashion. FEBS Lett 2000;476:272-6.
15. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A 1993;90:8424-8.
16. Williams-Simons L, Westphal H. EllaCre - utility of a general deleter strain. Transgenic Res 1999;8:53-4.
17. Matyakhina L, Pack S, Kirschner LS, et al. Chromosome 2 (2p16) abnormalities In Carney complex tumours. J Med Genet 2003;40:268-77.
18. Scacheri PC, Crabtree JS, Novotny EA, et al. Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 2001;30:259-63.
19. Xu X, Li C, Garrett-Beal L, Larson D, Wynshaw-Boris A, Deng CX. Direct removal in the mouse of a floxed neo gene from a three-loxP conditional knockout allele by two novel approaches. Genesis 2001;30:1-6.
20. Amieux PS, Howe DG, Knickerbocker H, et al. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J Biol Chem 2002;277:27294-304.
21. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004;64: 3718-24.
22. Carney JA, Boccon-Gibod L, Jarka DE, et al. Osteochondromyxoma of bone: a congenital tumor associated with lentigines and other unusual disorders. Am J Surg Pathol 2001;25:164-76.
23. Long P, Leininger J. Bone, joints and synovia. In: Maronpot R. Pathology of the mouse. Vienna (IL): Cache River Press: 1999. p.645-78.
24. Naf D, Krupke DM, Sundberg JP, Eppig JT, Bult CJ. The mouse tumor biology database: a public resource for cancer genetics and pathology of the mouse. Cancer Res 2002;62:1235-40.
25. Amieux PS, McKnight GS. The essential role of RIα in the maintenance of regulated PKA activity, Ann N Y Acad Sci 2002;968:75-95.
26. Tonks ID, Nurcombe V, Paterson C, et al. Tyroslnase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. Genesis 2003;37:131-8.
27. Veugelers M, Wilkes D, Burton K, et al. Comparative PRXAR1A genotype-phenotype analyses in humans with Carney complex and prkarla haploinsufficient mice. Proc Natl Acad Sci U S A 2004;101:14222-7.
28. Griffin KJ, Kirschner LS, Matyakhina L, et al. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res 2004;64:8811-5.
29. Griffin KJ, Kirschner LS, Matyakhina L, et al, A transgenic mouse bearing an antisense construct of regulatory subunit type IA of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet 2004;41:923-31.
30. Kim HA, DeClue JE, Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/ tyrosine kinase pathways. J Neurosci Res 1997;49: 236-47.
31. Raff MC, Hornby-Smith A, Brockes JP. Cyclic AMP as a mitogenic signal for cultured rat Schwann cells. Nature 1978;273:672-3.
32. Online Mendelian Inheritance in Man [database on the Internet]. Baltimore: McLusick-Nathans Institute for Genetic Medicine, Johns Hopkins University and Bethesda: National Center for Biotechnology Information, National Library of Medicine; 2003. Available from: http://www.ncbi.nlm.nih.gov/omim/.
33. McClatchey AI, Cichowski K. Mouse models of neurofibromatosis. Biochim Biophys Acta 2001;1471:M73-80.
34. Kim HA, Ratner N, Roberts TM, Stiles CD. Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J Neurosci 2001;21:1110-6.
35. Izawa I, Tamaki N, Saya H. Phosphorylation of neurofibromatosis type 1. gene product (neurofibromin) by cAMP-dependent protein kinase, FEBS Lett 1996;382: 53-9.
36. Alfthan K. Heiska L. Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 5] 8 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 2004;279:18559-66.
37. Albassam MA, Wojcinski ZW, Barsoum NJ, Smith GS. Spontaneous fibro-osseous proliferative lesions in the sternums and femurs of B6C3F1 mice. Vet Pathol 1991;28:381-8.
38. Sass B. Montali RJ. Spontaneous fibro-osseous lesions in aging female mice. Lab Anim Sci 1980;30: 907-9.
39. Weinstein LS, Shenker A, Gejman PV. Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
40. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P. Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997;151:1587-600.
41. Romanello M, Moro L, Pirulli D, Crovella S, D'Andrea P. Effects of cAMP on intercellular coupling and osteoblast differentiation. Biochem Biophys Res Commun 2001;282:1138-44.
42. Swarthout JT, Tyson DR, Jefcoat SC Jr, Partridge NC. Efcoat SC Jr. Induction of transcriptional activity of the cyclic adenosine monophosphate response element binding protein by parathyroid hormone and epidermal growth factor in osteoblastic cells. J Bone Miner Res 2002;17:1401-7.
43. Riminucci M, Liu B. Corsi A. et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gsα gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999;187:249-58.
44. Serra E, Rosenbaum T. Winner U, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000;9:3055-64.
45. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-2.
46. Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsαmutated skeletal progenitor cells. J Clin Invest 1998;101:1737-44.